$Purple Biotech (PPBT.US)$
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

$Purple Biotech (PPBT.US)$
Can Purple Biotech's Newly Patented Cancer Drug Combination Tackle Treatment Resistance?

$Purple Biotech (PPBT.US)$
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
Wednesday, 5th March at 7:00 am
NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer
REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-...

$Purple Biotech (PPBT.US)$
Revolutionary Cancer Drug NT219 Enters Phase 2 Trial Targeting $5B Market Opportunity

$Purple Biotech (PPBT.US)$
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
Tuesday, 18th February at 7:00 am
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux)
The study is conducted in collaboration with the University of Colorado Anschutz Medical Campus and is led by Dr. Antonio Jimeno, Professor and Director of ...

$Purple Biotech (PPBT.US)$
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
Thursday, 5th December at 7:13 am
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering o...

$Purple Biotech (PPBT.US)$ all in today

$Purple Biotech (PPBT.US)$
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
Tuesday, 3rd December at 8:23 am
REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced that it has entered into a definitive agreement for the purchase and sale of 472,...